Crinetics Pharmaceuticals
CRNX
CRNX
203 hedge funds and large institutions have $3.76B invested in Crinetics Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 78 increasing their positions, 55 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
21% more call options, than puts
Call options by funds: $34.1M | Put options by funds: $28.1M
12% more funds holding
Funds holding: 181 → 203 (+22)
3.54% less ownership
Funds ownership: 106.74% → 103.2% (-3.5%)
Holders
203
Holding in Top 10
13
Calls
$34.1M
Puts
$28.1M
Top Buyers
| 1 | +$100M | |
| 2 | +$71.7M | |
| 3 | +$67.1M | |
| 4 |
AG
Artal Group
Luxembourg
|
+$65.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.1M |
Top Sellers
| 1 | -$32M | |
| 2 | -$18.8M | |
| 3 | -$16M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$14.4M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$14.1M |